You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國家醫保藥品目錄公佈調整結果 新增74種藥品及調出11種藥品
國家醫療保障局召開新聞發佈會公佈2021年國家醫保藥品目錄調整結果。共計74種藥品新增進入目錄,11種藥品被調出目錄。據《新華網》報道,67種目錄外獨家藥品談判成功,平均降價61.71%,新納入藥品涉腫瘤、慢性病、抗感染、罕見病等領域。 2021年國家醫保藥品目錄內藥品總數2,860種,將於明年1月1日執行。調整後,國家醫保藥品目錄內藥品總數爲2,860種,其中西藥1,486種,中成藥1,374種。中藥飲片仍爲892種。在調整中,國家醫療保障局始終堅持「保基本」的功能定位,將基金可承受作爲必須堅守的「底線」,着力滿足廣大參保人基本用藥需求。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account